Dr. Faul earned his PhD title at the Albert Einstein College of Medicine in the Bronx in 2005, and conducted his postdoctoral research training at the Mount Sinai School of Medicine in New York City. He currently is an Associate Professor in the Division of Nephrology within the Department of Medicine and in the Department of Cell, Developmental and Integrative Biology (CDIB) at UAB.) He is also a member of the Comprehensive Diabetes Center and Section of Cardio-Renal Physiology and Medicine. He focuses on circulating fibroblast growth factors and their pathological effects on the heart in the context of diabetes and chronic kidney disease. In collaborations with pharma industry, Dr. Faul analyzes beneficial cardiac effects of pharmacological blockers for fibroblast growth factor receptors in animal models with diabetes and kidney injury. Dr. Faul received research funding from the American Diabetes Association (ADA), the American Society of Nephrology (ASN), and American Heart Association (AHA), and the NephCure Foundation, as well as support from pharma industry. Dr. White studied the molecular genetics of metabolic bone diseases during an NIH-sponsored postdoctoral fellowship at the Indiana University School of Medicine (IUSM). He played an instrumental role in discovering the novel hormone FGF23 during this time, and since then his laboratory has been funded to study FGF23 and its co-receptor Klotho. Within the University, he is Director of the MMGE Division of Molecular Genetics and Gene Therapy and currently a member of the Indiana Center for Musculoskeletal Health (ICMH). Dr. Gutiérrez is the Hilda B. Anderson Endowed Chair in Nephrology, Professor of Medicine and Epidemiology, Associate Director of the Division of Nephrology, and Deputy Director of the Center for Clinical and Translational Science at the University of Alabama at Birmingham (UAB). Dr. Gutiérrez’s research is focused on understanding pathophysiological mechanisms underlying disorders of phosphorus and vitamin D metabolism in health and in individuals with kidney disease. He has a special interest in delineating environmental and/or behavioral factors that may modulate these associations, particularly those related to health disparities, poverty and nutrition. To this end, his group conducts epidemiologic and patient-oriented studies investigating the impact of disturbances in phosphorus metabolism on kidney and cardiovascular health. He is funded by grants from the National Institutes of Health, the American Heart Association, and industry.

"…reviews the important role of fibroblast growth factor 23 (FGF23) and its association with human disease…. to provide an overview of the impact FGF23 has on different systems and offer a single resource for researchers to understand the larger scope of its utility…. [T]he first textbook fully dedicated to FGF23,…. it is critical to understand this protein as we learn to target these disease pathways…in many fields, including nephrology, bone metabolism, and cardiology. [A]uthored by established investigators studying FGF23 and Klotho who have shaped this line of research, as well as newer investigators who have expanded the field with novel insights…. [E]asy to read,… a unique and important book. As a provider in nephrology and bone metabolism, I have already referenced it on several occasions in review of patient cases." --©Doody’s Review Service, 2023, Jon Webb, MD (University of Kentucky College of Medicine)

• 1. The discovery of FGF23 – a historic view: genetic disorders of hypo- and hyperphosphatemia2. FGF23 – an established master regulator of phosphate metabolism3. FGF23 – more than a phosphaturic hormone4. The regulation of FGF23 production in bone and outside of bone5. Klotho-dependent actions of FGF23 - targets, signal transduction and cellular effects6. Klotho-independent actions of FGF23 - targets, signal transduction and cellular effects7. The experimental detection of FGF23 responsiveness and effects8. FGF23 and bone disease9. FGF23 and kidney disease10. FGF23 and heart and vascular disease11. FGF23 and inflammation, anemia, and iron12. FGF23 and infectious diseases13. FGF23 and lung disease14. FGF23 and neuro-cognitive disorders15. FGF23 as a drug target16. FGF23 – resolved issues, remaining controversies and future questions – a clinician’s perspective17. Klotho – the discovery of the FGF23 co-receptor18. Klotho – an FGF23-independent hormone19. Klotho and aging phenotypes20. αKlotho gene and protein measurements in humans and their role as a clinical biomarker of disease 21. Structural Basis of FGF23 Hormone Signaling22. Klotho – open questions, controversies and future perspectives23. The crosstalk between phosphate, FGF23 and klotho in the regulation of tissue homeostasis in health and disease